BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Radiology (1995) 68, 331-333
© 1995 British Institute of Radiology
doi: 10.1259/0007-1285-68-807-331
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anscher, M S
Right arrow Articles by Jirtle, R L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anscher, M S
Right arrow Articles by Jirtle, R L

Normal tissue injury after cancer therapy is a local response exacerbated by an endocrine effect of TGFβ

M S Anscher, MD F-M Kong, MD, PhD T Murase, MD and R L Jirtle, PhD

Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA

The sensitivity of normal tissues rather than of the tumour usually limits the effectiveness of cancer treatment. The normal tissue side effects from chemotherapy and/or radiotherapy result from both direct cellular loss and the extensive fibrosis that develops at the site of injury. Recent evidence suggests that the cytokine, transforming growth factor β (TGFβ), mediates this fibrogenic process. Herein, we provide evidence in support of the hypothesis that the fibrosis formation following therapy results not only from TGFβ produced locally in the injured normal tissue, but also from circulating TGFβ released by the tumour. Thus, therapy-induced normal tissue damage appears in part to be a local manifestation of a systemic condition.

Received for publication August 8, 1994. Accepted for publication October 26, 1994.




This article has been cited by other articles:


Home page
 In VivoHome page
R. M. JOHNKE, J. M. EDWARDS, M. J. EVANS, G. N. NANGAMI, N. T. G. BAKKEN, J. M. KILBURN, T.-K. LEE, R. R. ALLISON, U. L. KARLSSON, and H. H. ARASTU
Circulating Cytokine Levels in Prostate Cancer Patients Undergoing Radiation Therapy: Influence of Neoadjuvant Total Androgen Suppression
In Vivo, September 1, 2009; 23(5): 827 - 833.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. S. Muraoka-Cook, H. Kurokawa, Y. Koh, J. T. Forbes, L. R. Roebuck, M. H. Barcellos-Hoff, S. E. Moody, L. A. Chodosh, and C. L. Arteaga
Conditional Overexpression of Active Transforming Growth Factor {beta}1 In vivo Accelerates Metastases of Transgenic Mammary Tumors
Cancer Res., December 15, 2004; 64(24): 9002 - 9011.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Okunieff, E. Augustine, J. E. Hicks, T. L. Cornelison, R. M. Altemus, B. G. Naydich, I. Ding, A. K. Huser, E. H. Abraham, J. J. Smith, et al.
Pentoxifylline in the Treatment of Radiation-Induced Fibrosis
J. Clin. Oncol., June 1, 2004; 22(11): 2207 - 2213.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. S. Anscher, L. B. Marks, T. D. Shafman, R. Clough, H. Huang, A. Tisch, M. Munley, J. E. Herndon II, J. Garst, J. Crawford, et al.
Using Plasma Transforming Growth Factor Beta-1 During Radiotherapy to Select Patients for Dose Escalation
J. Clin. Oncol., September 1, 2001; 19(17): 3758 - 3765.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 1995 by the British Institute of Radiology.